Clinical improvement following interferon-α alone as an initial treatment in CIDP [2]

Muscle and Nerve

Volumn 23, Issue 2, 2000, Pages 295-296

  Harada, Hirotsugu ^a   Ohkoshi, Norio ^a   Fujita, Youshi ^a   Tamaoka, Akira ^a   Shoji, Shin'ichi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; CASE REPORT; CLINICAL PROTOCOL; DEMYELINATING NEUROPATHY; DRUG EFFICACY; HEPATITIS C; HUMAN; LETTER; MALE; MUSCLE STRENGTH; MUSCLE WEAKNESS; NERVE BIOPSY; NERVE CONDUCTION; PARESTHESIA; PRIORITY JOURNAL; SURAL NERVE; TREATMENT OUTCOME;

ADULT; DEMYELINATING DISEASES; HEPATITIS C, CHRONIC; HUMANS; IMMUNOTHERAPY; INTERFERON-ALPHA; MALE;

EID: 0033980407     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(200002)23:2<295::AID-MUS26>3.0.CO;2-C     Document Type: Letter

References (5)

1. Choudhary PP, Thompson N, Hughes RAC. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995;242:252-253.
2. Gorson KC, Ropper AH, Clark BD, Dew RB III, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α 2a. Neurology 1998;50: 84-87.
3. Noronha A, Toscas A, Jensen MA. Interferon-β decreases T cell activation and interferon-γ production in multiple sclerosis. J Neuroimmunol 1993;46:145-154.
4. Pollard JD. Class II antigen expression and T lymphocyte subsets in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol 1986;13:123-134.
5. Sabatelli M, Mignogna T, Lippi G, Milone M, Di Lazzaro V, Tonali P, Bertini E. Interferon-α may benefit steorid unresponsive chronic inflammatory neuropathy. J Neurol Neurosurg Psychiatry 1995;58:638-639.